Northwest Biotherapeutics (OTCMKTS:NWBO) Stock Passes Below 200-Day Moving Average - Here's Why

Key Points

• Shares fell below their 200‑day moving average: NWBO traded as low as $0.2031 and last at $0.21 (200‑day MA $0.24) on volume of ~2.43M shares, down about 2.2%.
• Clinical‑stage biotech with a Phase III lead: Northwest develops personalized dendritic‑cell immunotherapies and its lead candidate, DCVax‑L, is in a global Phase III trial for glioblastoma.
• Valuation and risk metrics: the company has a market capitalization of ~$344M, a negative P/E, and a beta of -0.74, reflecting a speculative/volatile profile.

Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO - Get Free Report) shares crossed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $0.24 and traded as low as $0.2031. Northwest Biotherapeutics shares last traded at $0.21, with a volume of 2,429,308 shares traded.

Northwest Biotherapeutics Stock Down 2.2%

The stock has a market capitalization of $344.03 million, a PE ratio of -0.01 and a beta of -0.74. The company has a 50-day moving average of $0.21 and a 200 day moving average of $0.24.

About Northwest Biotherapeutics

Northwest Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of personalized dendritic cell immunotherapies for the treatment of cancer. The company's proprietary platform harnesses patient-derived dendritic cells to present tumor-specific antigens and stimulate a targeted immune response. By tailoring each vaccine to the individual patient's tumor profile, the approach aims to improve outcomes and reduce off-target toxicity associated with conventional therapies.

The company's lead candidate, DCVax®-L, is designed for patients with newly diagnosed or recurrent glioblastoma multiforme (GBM) and has advanced through a global Phase III clinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.